The Korea Times
amn_close.png
amn_bl.png
National
  • Politics
  • Foreign Affairs
  • Multicultural Community
  • Defense
  • Environment & Animals
  • Law & Crime
  • Society
  • Health & Science
amn_bl.png
Business
  • Tech
  • Bio
  • Companies
  • World Expo 2030
amn_bl.png
Finance
  • Companies
  • Economy
  • Markets
  • Cryptocurrency
amn_bl.png
Opinion
  • Editorial
  • Columns
  • Thoughts of the Times
  • Cartoon
  • Today in History
  • Blogs
  • Tribune Service
  • Blondie & Garfield
  • Letter to President
  • Letter to the Editor
amn_bl.png
Lifestyle
  • Travel & Food
  • Trends
  • People & Events
  • Books
  • Around Town
  • Fortune Telling
amn_bl.png
Entertainment & Arts
  • K-pop
  • Films
  • Shows & Dramas
  • Music
  • Theater & Others
amn_bl.png
Sports
amn_bl.png
World
  • SCMP
  • Asia
amn_bl.png
Video
  • Korean Storytellers
  • POPKORN
  • Culture
  • People
  • News
amn_bl.png
Photos
  • Photo News
  • Darkroom
amn_NK.png amn_DR.png amn_LK.png amn_LE.png
  • bt_fb_on_2022.svgbt_fb_over_2022.svg
  • bt_twitter_on_2022.svgbt_twitter_over_2022.svg
  • bt_youtube_on_2022.svgbt_youtube_over_2022.svg
  • bt_instagram_on_2022.svgbt_instagram_over_2022.svg
The Korea Times
amn_close.png
amn_bl.png
National
  • Politics
  • Foreign Affairs
  • Multicultural Community
  • Defense
  • Environment & Animals
  • Law & Crime
  • Society
  • Health & Science
amn_bl.png
Business
  • Tech
  • Bio
  • Companies
  • World Expo 2030
amn_bl.png
Finance
  • Companies
  • Economy
  • Markets
  • Cryptocurrency
amn_bl.png
Opinion
  • Editorial
  • Columns
  • Thoughts of the Times
  • Cartoon
  • Today in History
  • Blogs
  • Tribune Service
  • Blondie & Garfield
  • Letter to President
  • Letter to the Editor
amn_bl.png
Lifestyle
  • Travel & Food
  • Trends
  • People & Events
  • Books
  • Around Town
  • Fortune Telling
amn_bl.png
Entertainment & Arts
  • K-pop
  • Films
  • Shows & Dramas
  • Music
  • Theater & Others
amn_bl.png
Sports
amn_bl.png
World
  • SCMP
  • Asia
amn_bl.png
Video
  • Korean Storytellers
  • POPKORN
  • Culture
  • People
  • News
amn_bl.png
Photos
  • Photo News
  • Darkroom
amn_NK.png amn_DR.png amn_LK.png amn_LE.png
  • bt_fb_on_2022.svgbt_fb_over_2022.svg
  • bt_twitter_on_2022.svgbt_twitter_over_2022.svg
  • bt_youtube_on_2022.svgbt_youtube_over_2022.svg
  • bt_instagram_on_2022.svgbt_instagram_over_2022.svg
  • Login
  • Register
  • Login
  • Register
  • The Korea Times
  • search
  • all menu
  • Login
  • Subscribe
  • Photos
  • Video
  • World
  • Sports
  • Opinion
  • Entertainment & Art
  • Lifestyle
  • Finance
  • Business
  • National
  • North Korea
  • 1

    14 injured as escalator reverses at Sunae Station in Bundang

  • 3

    Gov't to launch intensive crackdown against foreigners committing drug crimes

  • 5

    Ad or song?: Coca-Cola Zero ad featuring NewJeans becomes marketing blueprint

  • 7

    Netflix's new original 'Bloodhounds' to deliver cathartic action

  • 9

    Robot to conduct orchestra for 1st time in Korea

  • 11

    'Leaving Las Vegas' director Mike Figgis puts Korea in spotlight in new film

  • 13

    Dollar remittance, foreign exchange rules to be eased

  • 15

    NATO chief to chair emergency Ukraine meeting over dam

  • 17

    Canada wildfires shroud New York in apocalyptic haze

  • 19

    Tom Cruise to visit Seoul on June 29 to promote 'Mission: Impossible 7'

  • 2

    RM to attend Seoul festival to mark BTS' 10th anniv.

  • 4

    Dog meat traders condemn first lady, animal rights groups' push for ban

  • 6

    Korea falls to Italy in FIFA U-20 World Cup semifinals

  • 8

    INTERVIEWSpaceX's Starlink in Kyiv is wake-up call for Seoul

  • 10

    PHOTOSSubway escalator accident

  • 12

    Billy Graham Seoul Crusade celebrates 50th anniversary

  • 14

    Home gardening boom inspires plant adoption, specialized care services for leafy companions

  • 16

    Yoon's labor reform drive sputters as umbrella union exits talks

  • 18

    Korean businesses seek tougher punishments for industrial espionage

  • 20

    White Cube to open space in Seoul

Close scrollclosebutton

Close for 24 hours

Open
  • The Korea Times
  • search
  • all menu
  • Login
  • Subscribe
  • Photos
  • Video
  • World
  • Sports
  • Opinion
  • Entertainment & Art
  • Lifestyle
  • Finance
  • Business
  • National
  • North Korea
Business
  • Tech
  • Bio
  • Companies
  • World Expo 2030
Sat, June 10, 2023 | 00:45
Bio
HLB's US affiliate Verismo sets up Asia headquarters in Korea
Posted : 2022-02-15 17:16
Updated : 2022-02-15 17:48
Baek Byung-yeul
Print PreviewPrint Preview
Font Size UpFont Size Up
Font Size DownFont Size Down
  • facebook
  • twitter
  • kakaolink
  • whatsapp
  • reddit
  • mailto
  • link
HLB Group Chairman Jin Yang-gon, right, poses with Verismo Asia CEO Byung-girl Lee, second from left, and Verismo Therapeutics CEO Bryan Kim, second from right, Feb. 14. Courtesy of HLB
HLB Group Chairman Jin Yang-gon, right, poses with Verismo Asia CEO Byung-girl Lee, second from left, and Verismo Therapeutics CEO Bryan Kim, second from right, Feb. 14. Courtesy of HLB

By Baek Byung-yeul

Verismo Therapeutics, a new drug development company based in the U.S., established its Asia branch in Korea as part of its plan to facilitate clinical trials of its anti-cancer drug platform in the Asia region, the Korean biotech company HLB said Tuesday.

HLB Group is a major shareholder of Verismo Therapeutics, as HLB Pharmaceutical and HLB invested $10 million and $5 million, respectively, in 2021 to acquire a 30 percent stake in the U.S.-based company.

Verismo is a biotech company established by a University of Pennsylvania research team. The team led the development of Novartis' Kymriah, the world's first chimeric antigen receptor-T (CAR-T) treatment for hematological cancers approved by the U.S. Food and Drug Administration.

Verismo has its own SynKIR platform that can express a multi-chain receptor similar to the receptor structure mainly expressed in natural killer (NK) cells, which kills cancerous and virus-infected cells in the body. Among Verismo's many pipelines in development, SynKIR-110, the first pipeline for indications for pancreatic cancer, mesothelioma and ovarian cancer, is currently being prepared for an investigational new drug (IND) for phase 1 clinical trials in the U.S.

Its Asia branch will conduct development and clinical trials of the pipelines for Korea, Japan, China and others, by licensing SynKIR from Verismo. In addition, the company plans to expand its business areas by developing various other CAR T-cell therapies that can be specialized for the region's needs, by forming joint ventures with strategic biopharmaceutical partners in each country.

The Asia branch is on its way to establishing a partnership with a major medical center in Korea where it will not only conduct its first human clinical trials but also establish a manufacturing facility for T-cell products.

"Verismo Asia is working to be a leading CAR T-cell company in Asia by equipping various CAR T oncology pipelines, starting with the pancreatic cancer clinical trial of SynKIR-110 in Korea," Byung-girl Lee, CEO of Verismo Asia, said in a statement. "We are working to address key issues such as building a manufacturing facility and securing clinical hospitals."


Emailbaekby@koreatimes.co.kr Article ListMore articles by this reporter
 
wooribank
Top 10 Stories
1Rising minimum wage burdens small biz owners: survey Rising minimum wage burdens small biz owners: survey
2Resurging household loans pose challenge for BOK's rate policy Resurging household loans pose challenge for BOK's rate policy
3SPC bolsters PR activities in US SPC bolsters PR activities in US
4IPO market regains vigor on bullish KOSPI IPO market regains vigor on bullish KOSPI
5OpenAI explores investment opportunities in Korean startups: Sam AltmanOpenAI explores investment opportunities in Korean startups: Sam Altman
6China reaches out to Korean Assembly to counterweigh Yoon's bet on US China reaches out to Korean Assembly to counterweigh Yoon's bet on US
7Japanese business leaders pledge to support Busan's Expo bidJapanese business leaders pledge to support Busan's Expo bid
8Yoon's $40,000 GNI by 2027 goal seems unlikely prospectYoon's $40,000 GNI by 2027 goal seems unlikely prospect
9S. Korea may see rise in NK defectors as Pyongyang mulls reopening borders S. Korea may see rise in NK defectors as Pyongyang mulls reopening borders
10Hyundai Motor partners with Spider-Man animation to envision future mobility Hyundai Motor partners with Spider-Man animation to envision future mobility
Top 5 Entertainment News
1China's hallyu restrictions likely to continue unless Seoul-Beijing ties improve China's hallyu restrictions likely to continue unless Seoul-Beijing ties improve
2[INTERVIEW] CIX talks about team chemistry, youth theme INTERVIEWCIX talks about team chemistry, youth theme
3Gang Dong-won, Park Jeong-min team up for Joseon-era thriller 'War and Revolt' Gang Dong-won, Park Jeong-min team up for Joseon-era thriller 'War and Revolt'
4Netflix's new original 'Bloodhounds' to deliver cathartic actionNetflix's new original 'Bloodhounds' to deliver cathartic action
5'Leaving Las Vegas' director Mike Figgis puts Korea in spotlight in new film 'Leaving Las Vegas' director Mike Figgis puts Korea in spotlight in new film
DARKROOM
  • Turkey-Syria earthquake

    Turkey-Syria earthquake

  • Nepal plane crash

    Nepal plane crash

  • Brazil capital uprising

    Brazil capital uprising

  • Happy New Year 2023

    Happy New Year 2023

  • World Cup 2022 Final - Argentina vs France

    World Cup 2022 Final - Argentina vs France

CEO & Publisher : Oh Young-jin
Digital News Email : webmaster@koreatimes.co.kr
Tel : 02-724-2114
Online newspaper registration No : 서울,아52844
Date of registration : 2020.02.05
Masthead : The Korea Times
Copyright © koreatimes.co.kr. All rights reserved.
  • About Us
  • Introduction
  • History
  • Contact Us
  • Products & Services
  • Subscribe
  • E-paper
  • RSS Service
  • Content Sales
  • Site Map
  • Policy
  • Code of Ethics
  • Ombudsman
  • Privacy Statement
  • Terms of Service
  • Copyright Policy
  • Family Site
  • Hankook Ilbo
  • Dongwha Group